US$ 25.50
tirzepatide in nash the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly in persons with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary SURPASS to SURMOUNT: The Tirzepatide
Description
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study

It has been well established that GLP-1 RA is associated with improved glucose control and weight loss [18]

Despite the rise in chronic diseases related to lifestyle factors like diet, nutrition research only receives $2.2 billion of the $30 billion NIH budget

Safety Considerations and Potential Side Effects The most commonly reported side effects of GLP-1 medications include nausea, vomiting, diarrhea, and loss of appetiteeffects that typically diminish over time as the body adjusts

95% CI, 0.68-0.86
